Shay Capital’s 10x Genomics TXG Stock Holding History

Shay Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,500	Closed	-$418K	–	585
2023 Q1	$418K	Buy	+7,500	New	+$350K	0.08%	198

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

Shay Capital's TXG Position: Q2 2023 in Review

Shay Capital sold out of 10x Genomics (TXG) in Q2 2023, closing a stake of 7,500 shares — an estimated $418K sold.

Shay Capital first reported a position in TXG in Q1 2023 and held it in 1 quarter. The position peaked at $418K in Q1 2023. 274 funds tracked by Wall St. Rank hold TXG as of Q2 2023.

Shay Capital reported no remaining 10x Genomics position as of Q2 2023 after selling out during the quarter.
Shay Capital sold 7,500 10x Genomics shares in Q2 2023, an estimated $418K.
Shay Capital first reported a position in 10x Genomics in Q1 2023 and held it in 1 quarter.
Shay Capital's 10x Genomics position peaked at $418K in Q1 2023.
274 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2023.

Based on Shay Capital's 13F filing for Q2 2023, filed 14 Aug 2023.